EXPRESSION OF THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN NORMAL AND NEOPLASTIC BLOOD-CELLS AND HEMATOPOIETIC-TISSUE

被引:101
作者
PLESNER, T
RALFKIAER, E
WITTRUP, M
JOHNSEN, H
PYKE, C
PEDERSEN, TL
HANSEN, NE
DANO, K
机构
[1] UNIV COPENHAGEN,HERLEV HOSP,DEPT PATHOL,DK-2730 HERLEV,DENMARK
[2] UNIV COPENHAGEN,FINSEN LAB,DK-2730 HERLEV,DENMARK
[3] UNIV COPENHAGEN,RIGSHOSP,DEPT PATHOL,DK-2730 HERLEV,DENMARK
[4] UNIV COPENHAGEN,GENTOFTE HOSP,DEPT PATHOL,DK-2900 COPENHAGEN,DENMARK
关键词
LEUKEMIA; LYMPHOMA; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; UROKINASE TYPE PLASMINOGEN ACTIVATOR; NEUTROPHILS; MONOCYTES; MYELOID CELLS; DIFFERENTIATION ANTIGEN;
D O I
10.1093/ajcp/102.6.835
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Expression of the receptor for the urokinase type plasminogen activator (uPAR) has been studied by flow cytometry and immunohistology in normal blood and bone marrow cells, in vitro activated lymphoid cells, and tissue samples from reactive lymph nodes (n = 6), thymus (n = 2) and malignant lymphomas (n = 82), or leukemias (n = 32). HL-60 mgeloid precursor cells and CD34-positive normal stem cells also were analyzed. In the normal cells, staining was confined to monocytes, macrophages, neutrophils, and myeloid precursors. No labelling was seen of normal or activated lymphoid cells. Purified CD34-positive hematopoietic progenitors were uPAR negative, but expressed uPAR during differentiation in short-term liquid culture stimulated in vitro by recombinant interleukin (IL)-1, IL-3, IL-6, granulocyte-macrophage colony stimulating factor (CSF), granulocyte-CSF, and stem cell factor. Enhanced uPAR expression was also seen in HL60 cells after induction of differentiation with dimethyl sulfoxide or 1 alpha,25-dihydroxyvitamin D-3. In lymphomas and leukemias, the staining pattern was similar to that seen in the normal cells with labelling of monocytic and myeloid malignancies, but not of the neoplastic cells in B-cell or T-cell lymphomas or Hodgkin's disease. In conclusion, uPAR is a differentiation marker for myeloid and monocytic cells, and may act to facilitate migration of these cells in normal and pathologic conditions by cell-associated plasminogen activation. Whether expression of uPAR in myeloid and monocytic malignancies relates to their growth and behavior will be an important topic for investigations in the future.
引用
收藏
页码:835 / 841
页数:7
相关论文
共 54 条
[21]   HUMAN-ENDOTHELIAL CELLS CONTAIN ONE TYPE OF PLASMINOGEN-ACTIVATOR [J].
KRISTENSEN, P ;
LARSSON, LI ;
NIELSEN, LS ;
GRONDAHLHANSEN, J ;
ANDREASEN, PA ;
DANO, K .
FEBS LETTERS, 1984, 168 (01) :33-37
[22]   HISTIOCYTIC SARCOMAS AND MONOBLASTIC LEUKEMIAS - A CLINICAL, HISTOLOGIC, AND IMMUNOPHENOTYPICAL STUDY [J].
LAURITZEN, AF ;
DELSOL, G ;
HANSEN, NE ;
HORN, T ;
ERSBOLL, J ;
HOUJENSEN, K ;
RALFKIAER, E .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (01) :45-54
[23]  
LIU DY, 1986, J IMMUNOL, V137, P448
[24]  
MILES LA, 1987, THROMB HAEMOSTASIS, V58, P936
[25]  
MIN HY, 1992, J IMMUNOL, V148, P3636
[26]  
MIZUKAMI IF, 1990, J IMMUNOL, V144, P1841
[27]  
NIELSEN LS, 1988, J BIOL CHEM, V263, P2358
[28]   IDENTIFICATION AND CHARACTERIZATION OF UROKINASE RECEPTORS IN NATURAL-KILLER-CELLS AND T-CELL-DERIVED LYMPHOKINE ACTIVATED KILLER-CELLS [J].
NYKJAER, A ;
PETERSEN, CM ;
MOLLER, B ;
ANDREASEN, PA ;
GLIEMANN, J .
FEBS LETTERS, 1992, 300 (01) :13-17
[29]  
NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V152, P399
[30]  
ODEKON LE, 1992, CIRC SHOCK, V37, P169